GeoVax Congratulates Bipartisan Senate Action to Onshore Critical Medical Manufacturing
Highlights Broad National Support for Domestic Vaccine Resilience and Role of MVA Platform in Public Health Preparedness
ATLANTA, GA - May 29, 2025 ( NEWMEDIAWIRE ) - GeoVax Labs, Inc. (Nasdaq: GOVX), a clinical-stage biotechnology company developing multi-antigen vaccines and immunotherapies, voiced strong support for the newly announced bipartisan initiative by U.S. Senators Joni Ernst (R-IA) and Lisa Blunt Rochester (D-DE) to onshore the manufacturing of critical pharmaceutical supplies. The Critical Infrastructure Manufacturing Feasibility Act seeks to reduce reliance on foreign sources for key medical products - directly aligning with GeoVax's mission to rebuild U.S.-based vaccine manufacturing and strengthen national preparedness.
'We are seeing a unified, national groundswell - from Congress, the White House, HHS, FDA, BARDA, and commissions like NSCEB - calling for the onshoring of America's vaccine manufacturing base,' said David Dodd, Chairman and CEO of GeoVax. 'GeoVax is purpose-built to answer that call, with a clinically validated MVA platform, a domestic manufacturing strategy, and a focus on pandemic responsiveness and protection of the immunocompromised.'
Rebuilding U.S. Biomanufacturing Through Coordinated Federal Action
The Senate initiative complements a cascade of government actions to bring the manufacturing of essential medical countermeasures - including vaccines - back to U.S. soil including:
These actions reflect growing bipartisan recognition that national health security depends on resilient, scalable domestic vaccine capacity.
MVA Technology: Protecting the Immunocompromised with Durable, Multi-Antigen Vaccines
GeoVax's MVA platform supports a pipeline of multi-antigen vaccines, including GEO-CM04S1 (COVID-19), primarily targeted to address the current unmet needs inducing broad T-cell and antibody responses among immunocompromised individuals, overcoming the limitations of single-antigen vaccines.
GeoVax's MVA vaccines align with FDA and HHS goals to advance diversified, multi-antigenic strategies that provide broader, longer-lasting protection across high-risk groups.
Enabling U.S. Biomanufacturing Through Equip-A and BARDA RRPV: A Roadmap to Rapid, U.S.-Based Vaccine Production
GeoVax's progressing advanced MVA manufacturing process is anticipated to eliminate the need for pathogen-free eggs and leverage a continuous avian cell line system, directly supporting the objectives of the federal government's EQUIP-A-Pharma initiative. This HHS-ASPR-DARPA program aims to create agile, point-of-care pharmaceutical production capabilities using modular, AI-driven platforms.
Additionally, GeoVax's proposal - 'Innovation in Clinical Manufacturing of MVA-Vectored COVID-19 Vaccines' - was selected by BARDA's Rapid Response Partnership Vehicle (RRPV), pending funding availability. The program is designed to accelerate the scale-up of advanced U.S.-based MVA vaccine manufacturing. The proposal is designed to:
If funded, this effort is expected to create a scalable, resilient domestic manufacturing platform essential for the rapid deployment of MVA-based vaccines like GEO-CM04S1 (COVID-19) and GEO-MVA (Mpox/smallpox).
Platform Alignment with National Priorities
GeoVax's MVA-based vaccines embody the shift in U.S. public health strategy away from single-antigen platforms and toward multi-antigen, durable, and safe alternatives. These vaccines are specifically engineered to meet the needs of high-risk populations - including the 40+ million immunocompromised Americans who may not respond effectively to mRNA and other vaccines that focus primarily on inducing antibody immunity.
GeoVax's U.S.-controlled MVA platform addresses key government objectives:
Call for Continued Bipartisan Momentum
'With renewed bipartisan focus on U.S. medical independence, there is no better time to invest in American-homegrown vaccine innovation,' added Dodd. 'We urge lawmakers and federal agencies to continue supporting domestic capacity, biodefense readiness, and equitable access to advanced medical countermeasures to protect both our national security and our most vulnerable populations.'
About GeoVax
GeoVax Labs, Inc. is a clinical-stage biotechnology company developing novel vaccines against infectious diseases and therapies for solid tumor cancers. The Company's lead clinical program is GEO-CM04S1, a next-generation COVID-19 vaccine currently in three Phase 2 clinical trials, being evaluated as (1) a primary vaccine for immunocompromised patients such as those suffering from hematologic cancers and other patient populations for whom the current authorized COVID-19 vaccines are insufficient, (2) a booster vaccine in patients with chronic lymphocytic leukemia (CLL) and (3) a more robust, durable COVID-19 booster among healthy patients who previously received the mRNA vaccines. In oncology the lead clinical program is evaluating a novel oncolytic solid tumor gene-directed therapy, Gedeptin(R), having recently completed a multicenter Phase 1/2 clinical trial for advanced head and neck cancers. The Company is also developing GEO-MVA, a vaccine targeting Mpox and smallpox. GeoVax has a strong IP portfolio in support of its technologies and product candidates, holding worldwide rights for its technologies and products. For more information about the current status of our clinical trials and other updates, visit our website: www.geovax.com.
Forward-Looking Statements
This release contains forward-looking statements regarding GeoVax's business plans. The words 'believe,' 'look forward to,' 'may,' 'estimate,' 'continue,' 'anticipate,' 'intend,' 'should,' 'plan,' 'could,' 'target,' 'potential,' 'is likely,' 'will,' 'expect' and similar expressions, as they relate to us, are intended to identify forward-looking statements. We have based these forward-looking statements largely on our current expectations and projections about future events and financial trends that we believe may affect our financial condition, results of operations, business strategy and financial needs. Actual results may differ materially from those included in these statements due to a variety of factors, including whether: GeoVax is able to obtain acceptable results from ongoing or future clinical trials of its investigational products, GeoVax's immuno-oncology products and preventative vaccines can provoke the desired responses, and those products or vaccines can be used effectively, GeoVax's viral vector technology adequately amplifies immune responses to cancer antigens, GeoVax can develop and manufacture its immuno-oncology products and preventative vaccines with the desired characteristics in a timely manner, GeoVax's immuno-oncology products and preventative vaccines will be safe for human use, GeoVax's vaccines will effectively prevent targeted infections in humans, GeoVax's immuno-oncology products and preventative vaccines will receive regulatory approvals necessary to be licensed and marketed, GeoVax raises required capital to complete development, there is development of competitive products that may be more effective or easier to use than GeoVax's products, GeoVax will be able to enter into favorable manufacturing and distribution agreements, and other factors, over which GeoVax has no control.
Further information on our risk factors is contained in our periodic reports on Form 10-Q and Form 10-K that we have filed and will file with the SEC. Any forward-looking statement made by us herein speaks only as of the date on which it is made. Factors or events that could cause our actual results to differ may emerge from time to time, and it is not possible for us to predict all of them. We undertake no obligation to publicly update any forward-looking statement, whether as a result of new information, future developments or otherwise, except as may be required by law.
Company Contact:
[email protected]
678-384-7220
Investor Relations Contact:
[email protected]
212-698-8696
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
36 minutes ago
- Yahoo
A crucial jobs report meets a stock market at all-time highs: What to know this week
The S&P 500 (^GSPC) is back at an all-time high for the first time since February as optimism around Federal Reserve interest rate cuts and fading fears of tariffs have driven stocks higher. In the final full trading week of June, the S&P 500 rose 3.5%, while the Nasdaq Composite (^IXIC) rose more than 4.1%. Both indexes ended the week at all-time highs. Meanwhile, the Dow Jones Industrial Average (^DJI) added about 3.8%. The June jobs report will headline the first week of July. Fresh readings on job openings and wage data, as well as manufacturing and services activity, will also be in focus for investors. Investors will also have a close eye on any updates regarding President Trump's various tariff pauses ahead of the administration's self-imposed tariff delay deadline on July 9. Markets will close at 1 p.m. on Thursday and remain shut on Friday for the Fourth of July. Markets are increasingly optimistic that the Federal Reserve may cut interest rates soon. As of Friday, markets were pricing in an 18.6% chance the central bank cuts interest rates at its next meeting in late July, up from a 14.5% chance seen last week, per the CME FedWatch Tool. Meanwhile, probability investors are placing on a cut by the end of September has surged, with markets now pricing in a 93% chance the central bank will have lowered rates by then, up from a 70% chance seen just a week ago. The shift comes as several Fed officials have alluded to the possibility of cutting interest rates as soon as the central bank's July meeting. In a speech on June 23, Federal Reserve governor Michelle Bowman noted that although the labor market is showing signs of strength, it "appears to be less dynamic." "With inflation on a sustained trajectory toward 2%, softness in aggregate demand, and signs of fragility in the labor market, I think that we should put more weight on downside risks to our employment mandate going forward," Bowman said. However, Fed Chair Jerome Powell has been more cautious about interest rate cuts. While testifying in front of House lawmakers last week, Powell stressed that the central bank is "well-positioned to wait" before moving interest rates. EY chief economist Greg Daco told Yahoo Finance he believes the Fed will likely cut in September. "By then we will have seen more demand erosion, we will have seen a labor market that unfortunately has slowed and income growth as a result has slowed, leading to slower consumer spending activity," Daco said. Signs of cooling in the labor market have been a key part of the brewing debate over Fed policy and will put further emphasis on the incoming June jobs report, due out for release at 8:30 a.m. ET on Thursday. Economists expect the report to show 116,00 nonfarm payrolls were added, a move lower from the 139,000 seen in May. The unemployment rate is anticipated to have moved up to 4.3% from 4.2% the month prior. "We expect the moderation in hiring to continue," Wells Fargo's team of economists led by Jay Bryson wrote in a note to clients on Friday. " Demand for new workers remains muted amid still-elevated uncertainty, restrictive monetary policy and the ongoing federal government hiring freeze." The S&P 500's most recent record close comes as the market has rallied more than 23% from its April 8 bottom. Now, strategists believe the market's largest tariff fears are behind investors. Economic forecasts have once again begun reverting higher, along with projections for corporate earnings this year. And Wall Street strategists are becoming incrementally bullish on the outlook from here. As our chart below shows, the S&P 500 has chugged past a slew of headwinds to hit a record high this year. "The market still does tend to have a bullish sentiment to it," Charles Schwab head of trading and derivatives strategist Joe Mazzola told Yahoo Finance. "So I think you're seeing investors looking for those opportunities on pullbacks to buy in." Weekly Calendar Earnings: No notable earnings releases. Economic data: MNI Chicago PMI, June (42.7 expected, 40.5 prior); Dallas Fed manufacturing activity Earnings: Constellation Brands (STZ) Economic data: JOLTS Job Openings, May (7.26 million expected, 7.39 previously); ISM manufacturing, June (48.8 expected, 48.5 prior); Construction spending month-over-month, May (+0.1% expected, -0.4% prior); Dallas Fed services activity (-10.1 prior); S&P Global US manufacturing PMI, June (52 expected, 52 prior) Wednesday Earnings: No notable earnings. Economic data: MBA Mortgage Applications, week ending June 27 (+1.1% previously); ADP employment change, June (90,000 expected, 37,000 expected); S&P Global US services PMI, May final (52.3 expected, 52.3 prior); Challenger job cuts year-over-year, May (+62.7% prior) Earnings: No notable earnings Economic data: Nonfarm payrolls, June (+110,000 expected, +129,000 previously); Unemployment rate, June (4.3% expected, 4.2% previously); Average hourly earnings, month over month, June (+0.3% expected, +0.4% previously); Average hourly earnings, year over year, June (+3.8% expected, +3.9% previously); Average weekly hours worked, June (34.3 expected, 34.3 previously); Labor force participation rate, June (62.5% expected, 62.4% previously); Initial jobless claims week ending June 28 (240,000 expected, 236,000 prior); Continuing claims week ending May 24 (1.91 million prior); Nonfarm productivity, first quarter final (-0.8% expected, -0.8% prior); Unit labor costs, first quarter final (+5.7% expected, +5.7% prior); S&P Global US Composite PMI, June final (52.8 prior); ISM Services index, June (50.7 expected, 49.4prior); Federal Reserve Beige Book released; Durable goods orders, May final (16.4% prior) Markets are closed for the Fourth of July. Josh Schafer is a reporter for Yahoo Finance. Follow him on X @_joshschafer.
Yahoo
an hour ago
- Yahoo
What Does Palo Alto Networks, Inc.'s (NASDAQ:PANW) Share Price Indicate?
Let's talk about the popular Palo Alto Networks, Inc. (NASDAQ:PANW). The company's shares received a lot of attention from a substantial price increase on the NASDAQGS over the last few months. The company is now trading at yearly-high levels following the recent surge in its share price. As a large-cap stock with high coverage by analysts, you could assume any recent changes in the company's outlook is already priced into the stock. However, what if the stock is still a bargain? Let's examine Palo Alto Networks's valuation and outlook in more detail to determine if there's still a bargain opportunity. Trump has pledged to "unleash" American oil and gas and these 15 US stocks have developments that are poised to benefit. The stock seems fairly valued at the moment according to our valuation model. It's trading around 15% below our intrinsic value, which means if you buy Palo Alto Networks today, you'd be paying a reasonable price for it. And if you believe the company's true value is $235.49, then there's not much of an upside to gain from mispricing. Furthermore, Palo Alto Networks's low beta implies that the stock is less volatile than the wider market. See our latest analysis for Palo Alto Networks Future outlook is an important aspect when you're looking at buying a stock, especially if you are an investor looking for growth in your portfolio. Buying a great company with a robust outlook at a cheap price is always a good investment, so let's also take a look at the company's future expectations. Palo Alto Networks' earnings over the next few years are expected to increase by 86%, indicating a highly optimistic future ahead. This should lead to more robust cash flows, feeding into a higher share value. Are you a shareholder? PANW's optimistic future growth appears to have been factored into the current share price, with shares trading around its fair value. However, there are also other important factors which we haven't considered today, such as the financial strength of the company. Have these factors changed since the last time you looked at the stock? Will you have enough confidence to invest in the company should the price drop below its fair value? Are you a potential investor? If you've been keeping tabs on PANW, now may not be the most optimal time to buy, given it is trading around its fair value. However, the positive outlook is encouraging for the company, which means it's worth diving deeper into other factors such as the strength of its balance sheet, in order to take advantage of the next price drop. So if you'd like to dive deeper into this stock, it's crucial to consider any risks it's facing. Every company has risks, and we've spotted 1 warning sign for Palo Alto Networks you should know about. If you are no longer interested in Palo Alto Networks, you can use our free platform to see our list of over 50 other stocks with a high growth potential. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
an hour ago
- Yahoo
Johnson & Johnson's (JNJ) IMAAVY Demonstrates Superior gMG Control
Johnson & Johnson (NYSE:JNJ) is one of the 12 stocks that will make you rich in 10 years. On June 23, J&J announced new data from an indirect treatment comparison (ITC) study. The data show that the company's drug, IMAAVY (nipocalimab-aahu), demonstrated consistent and sustained disease control in patients with generalized myasthenia gravis (gMG) compared to other approved FcRn blockers. The findings were presented at the European Academy of Neurology (EAN) 2025 Congress in Helsinki, Finland. Gil C/ According to the findings, IMAAVY showed a comparable onset of symptom relief at Week 1. The drug demonstrated consistent and sustained disease control over multiple timepoints up to 24 weeks. More importantly, IMAAVY showed greater or statistically significant improvement in Myasthenia Gravis Activities of Daily Living (MG-ADL) scores compared to the published Phase 3 data of other FcRn blockers. The drug received FDA approval on April 30, 2025, for adults and pediatric patients aged 12 and older with anti-AChR or anti-MuSK antibody-positive gMG. This makes IMAAVY the first and only FcRn blocker approved for both antibody types, covering ≥90% of antibody-positive gMG patients. Johnson & Johnson (NYSE:JNJ) is a global healthcare company. It develops, manufactures, and sells pharmaceuticals and medical devices through two main segments: Innovative Medicine and MedTech. Its key pharmaceutical products include Darzalex, Stelara, Tremfya, and Carvykti, while its MedTech offerings span surgical technologies, orthopedics, and vision care. While we acknowledge the potential of JNJ as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: and . Disclosure: None. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
